Curanex Pharmaceuticals (CURX) Non-Current Assets (2025)

Curanex Pharmaceuticals' (CURX) quarterly Non-Current Assets came in at $352616.0 in Q4 2025, up 483.82% on a QoQ basis from $60398.0 in Q3 2025.

Curanex Pharmaceuticals (CURX) Non-Current Assets (2025) Analysis & Trends

Curanex Pharmaceuticals (CURX) has 1 years of Non-Current Assets data on file, last reported at $352616.0 in Q4 2025.

Quarterly Non-Current Assets changed N/A year-over-year to $352616.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $488851.0 (changed N/A YoY) and the FY2025 annual result came in at $352616.0, changed N/A from the prior year.
Non-Current Assets improved to $352616.0 in Q4 2025, from $60398.0 in the prior quarter.
In the past five years, Non-Current Assets ranged from a high of $352616.0 in Q4 2025 to a low of $60398.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.96 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	938.60 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	468.65 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	18.06 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	6.80 Bn
10	Curanex Pharmaceuticals	6.11 Mn	1.11 Mn	-	352,616.00

Download Data